Comparing Trulance and Linzess: Which might suit your specific needs?
Trulance (plecanatide) and Linzess (linaclotide) are brand-name prescription medications approved by the Food and Drug Administration (FDA) to treat two types of constipation in adults. Both drugs are guanylate cyclase-C (GC-C) agonists, with similar mechanisms to increase intestinal fluid and transit.
Efficacy
Both Trulance and Linzess have shown initial effectiveness in treating irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). However, individual responses may vary. Some patients have reported that Trulance provided initial full bowel movements and reduced bloating but later diminished in effectiveness, while others switch from long-term Linzess use to Trulance seeking better symptom control.
Linzess has been marketed more aggressively and has a broader indication spectrum, implying strong clinical acceptance and possibly more robust data on efficacy.
Side Effects
Common side effects of both medications include diarrhea, abdominal pain, and bloating. There is anecdotal evidence of severe bloating and nausea in patients with CIC, sometimes persisting despite treatment. Some patients report that Linzess's side effects can be bothersome but are balanced by its effectiveness, while fears of side effects can affect acceptance of other treatments like prucalopride.
Safety
Both drugs are considered generally safe when used as prescribed for IBS-C and CIC. They have similar warnings, including contraindications in pediatric patients and those with known or suspected mechanical gastrointestinal obstruction. No significant drug interaction differences were highlighted in the data reviewed.
However, both Trulance and Linzess have a boxed warning for the risk of serious dehydration in certain children. Animal studies of Trulance and Linzess found an increased risk of serious dehydration (due to diarrhea) in young animals given these drugs. However, it's not known for certain whether Trulance and Linzess increase the risk of dehydration in children.
Dosage and Form
For IBS-C, the dose of Trulance is 3 mg once daily, with or without food, while the dose of Linzess is 290 mcg once daily on an empty stomach, at least 30 minutes prior to the first meal of the day. For CIC, the dose of Trulance is 3 mg once daily, with or without food, while the dose of Linzess is 72 mcg or 145 mcg once daily on an empty stomach, at least 30 minutes prior to the first meal of the day.
Trulance is an oral tablet, while Linzess is an oral capsule.
Availability and Cost
The generic status for Trulance and Linzess is that they are not currently available as generics. The cost of Trulance or Linzess depends on the treatment plan prescribed by a doctor, the insurance plan, and the pharmacy.
Conclusion
In summary, Trulance and Linzess have comparable efficacy and safety profiles as GC-C agonists for IBS-C and CIC. Individual patient experience may vary, with some preferring Trulance for initial symptom relief and others relying on Linzess for its broader clinical use and longer market presence. Treatment choice often depends on patient tolerance, physician preference, and insurance coverage considerations.
If you'd like to learn more about Trulance or Linzess, talk with your doctor or pharmacist. They can help answer any questions you have about similarities and differences between the drugs and determine if one drug or the other might work well for you.
Anthrax, a severe medical-condition, is not a known side effect of Trulance or Linzess, but digestive health issues like diarrhea, abdominal pain, and bloating are common side effects. Science has shown that these medications can have an impact on health-and-wellness, particularly in managing constipation and related medical-conditions like irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).
